UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number 001-40979 Solo Brands, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 87-1360865 S ...

Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Woburn, MA, November 6, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a business update. The Company announced on October 20, 2025, that the U.S. Food and Drug Administration (FDA) has accepted the BLA r ...

WHITE MOUNTAINS REPORTS THIRD QUARTER RESULTS HAMILTON, Bermuda (November 6, 2025) - White Mountains Insurance Group, Ltd. (NYSE: WTM) reported book value per share of $1,851 as of September 30, 2025, an increase of 3% for the third quarter of 2025 and 6% for the first nine months of 2025, including dividends. On October 2, 2025, White Mountains entered into an agreement to sell approximately 77% of its equity interest in Bamboo for cash to CVC Capital Partners and will retain the remainder. Including the e ...

Exhibit 99 Release Date: Immediate November 5, 2025 Natalie M. Fischer 6363 Main Street/Williamsville, NY 14221 Investor Relations 716-857-7315 Timothy J. Silverstein Chief Financial Officer 716-857-6987 NATIONAL FUEL REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2025 EARNINGS WILLIAMSVILLE, N.Y.: National Fuel Gas Company ("National Fuel" or the "Company") (NYSE:NFG) today announced consolidated results for the three months and fiscal year ended September 30, 2025. FOURTH QUARTER FISCAL 2025 SUMMARY FISCAL 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-40693 RALLYBIO CORP ...

Dentsply Sirona Reports Third Quarter 2025Results Charlotte, N.C., November 6, 2025 - DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2025 and introduced its Return-to-Growth action plan, a comprehensive strategy to improve performance and position the Company for sustained, profitable growth over the next 24 months. Third quarter net sales of $904 million decreased (5.0%) (decreased (8.0%) in constant currency) compared ...

Mr. Louvet continued, "As we continue to navigate a highly dynamic global operating environment with agility, we are encouraged by our brand's continued momentum through the start of the important Fall/Holiday season, enabling us to once again raise our Fiscal 2026 outlook." 1 EXHIBIT 99.1 RALPH LAUREN REPORTS BETTER THAN EXPECTED SECOND QUARTER FISCAL 2026 RESULTS AND RAISES FULL YEAR OUTLOOK NEW YORK -- (BUSINESS WIRE) -- November 6, 2025 -- Ralph Lauren Corporation (NYSE:RL), a global leader in the desig ...

Exhibit 99.1 Corporate Updates • In the third quarter of 2025, Rallybio generated a total of $20 million pursuant to its agreement with Recursion Pharmaceuticals for the sale of its interest in REV102, an investigational ENPP1 inhibitor in development for the treatment of hypophosphatasia (HPP). The total included $7.5 million from an upfront payment and $12.5 million related to the initiation of additional preclinical studies. RLYB116 Program Rallybio Reports Third Quarter 2025 Financial Results and Provid ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 000-24993 _______________________ ...

Financial Performance - Total current assets increased to $397,502,000 as of September 30, 2025, up from $267,286,000 as of December 31, 2024, representing a 48.7% increase[15] - Net loss for the three months ended September 30, 2025, was $21,618,000, compared to a net loss of $18,142,000 for the same period in 2024, indicating a 13.6% increase in losses[18] - The company reported total operating expenses of $23,926,000 for the three months ended September 30, 2025, up from $19,612,000 in the same period of 2024, a 22.5% increase[18] - The company experienced a total comprehensive loss of $21,475,000 for the three months ended September 30, 2025, compared to a loss of $18,021,000 for the same period in 2024, a 13.6% increase[18] - The net loss for the nine months ended September 30, 2025, was $64.9 million, compared to a net loss of $46.3 million for the same period in 2024[25] - The net loss attributable to common stockholders for the nine months ended September 30, 2025, was $64,909,000, compared to $46,336,000 for the same period in 2024, representing a 40.3% increase[74] Research and Development - Research and development expenses for the three months ended September 30, 2025, were $19,270,000, compared to $16,747,000 for the same period in 2024, reflecting a 9.1% increase[18] - Canvuparatide (MBX 2109) incurred direct research and development expenses of $10.1 million for the three months ended September 30, 2025, compared to $6.0 million in 2024, a 70% increase[106] - Direct program expense for canvuparatide was $10,130,000 for the three months ended September 30, 2025, compared to $5,957,000 in 2024, indicating a 69.5% increase[79] - Research and development expenses increased to $59.4 million for the nine months ended September 30, 2025, up from $42.2 million in the same period of 2024, representing a $17.2 million increase[112] - Direct research and development program expenses for canvuparatide rose by $12.5 million, primarily due to increased activities related to the Phase 2 clinical trial and preparation for the Phase 3 trial[112] Cash and Equity - Cash and cash equivalents significantly increased to $223,125,000 as of September 30, 2025, compared to $49,351,000 as of December 31, 2024, a growth of 351.5%[15] - The company generated approximately $401.8 million in aggregate gross proceeds from various stock issuances since inception, with an additional $199.9 million raised in September 2025[29] - Cash and cash equivalents at the end of the period were $223.1 million, up from $132.9 million at the end of the same period in 2024[25] - As of September 30, 2025, the Company had cash, cash equivalents, and marketable securities totaling $391.7 million, which management believes will be sufficient to fund obligations for at least 12 months[30] - The company reported a weighted average number of common shares outstanding of 34,198,597 for the three months ended September 30, 2025, compared to 6,515,616 in 2024, indicating a significant increase in shares[74] Operating Expenses - The company reported total operating expenses of $23,926,000 for the three months ended September 30, 2025, up from $19,612,000 in the same period of 2024, a 22.5% increase[18] - General and administrative expenses were $12.9 million for the nine months ended September 30, 2025, compared to $7.4 million for the same period in 2024, reflecting a $5.5 million increase[113] - The company anticipates significant increases in operating expenses as it advances the development of its product candidates and transitions to commercial activities[88] Financing Activities - The company reported a net cash provided by financing activities of $189.2 million for the nine months ended September 30, 2025[25] - The company completed an underwritten public offering of 11,108,055 shares, resulting in approximately $199.9 million in gross proceeds[29] - The company completed its IPO on September 16, 2024, issuing 11,730,000 shares at $16.00 per share, resulting in net proceeds of $170.5 million[60] Market and Regulatory Risks - Changes in U.S. federal tax laws, such as the One Big Beautiful Bill Act, may adversely affect the company's financial condition and cash flow[147] - Ongoing healthcare legislative and regulatory reforms may have a material adverse effect on the company's business and results of operations[148] - The company faces risks related to potential price controls and cost-containment measures that could limit revenue from approved products[150] - The company is subject to heightened governmental scrutiny over pricing methodologies, which may lead to changes in reimbursement rates and coverage policies[151] - The Inflation Reduction Act of 2022 (IRA) will reduce out-of-pocket spending cap for Medicare Part D beneficiaries to $2,000 starting in 2025, impacting drug pricing and manufacturer patient programs[152] Corporate Structure and Operations - The company maintains its corporate offices in Carmel, Indiana, and was organized in August 2018[28] - The Company has entered into a lease agreement for its principal executive office, which has been extended through December 31, 2028, following a modification in May 2025[47] - The Company triggered a $1.0 million milestone payment related to the initiation of the Phase 1 clinical trial of MBX 4291, with total future milestone payments in the License Agreement amounting to $9.3 million[54] Future Outlook - The lead product candidate, canvuparatide, is expected to enter Phase 3 clinical trials in the third quarter of 2026 following positive results from Phase 2 trials[83] - The company plans to present results from the Phase 2 clinical trial of canvuparatide at a medical meeting in the second quarter of 2026[83] - The company expects substantial increases in expenses as it advances the development of its product candidates and incurs additional costs associated with operating as a public company[116]